PT  - JOURNAL ARTICLE
AU  - Baumeister, Sebastian-Edgar
AU  - Nolde, Michael
AU  - Alayash, Zoheir
AU  - Leitzmann, Michael
AU  - Baurecht, Hansjörg
AU  - Meisinger, Christa
TI  - Cannabis use and risk of type 2 diabetes: a two-sample Mendelian randomization study
AID  - 10.1101/2020.09.21.20197343
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.21.20197343
4099  - http://medrxiv.org/content/early/2020/09/24/2020.09.21.20197343.short
4100  - http://medrxiv.org/content/early/2020/09/24/2020.09.21.20197343.full
AB  - Cannabis has effects on the insulin/glucose metabolism. As the use of cannabis and the prevalence of type 2 diabetes increase worldwide, it is important to examine the effect of cannabis on the risk of diabetes. We conducted a Mendelian randomization study by using 19 single-nucleotide polymorphisms as instrumental variables for lifetime cannabis use and 14 SNPs to instrument cannabis use disorder, and linking these to type 2 diabetes risk using genome-wide association study data (lifetime cannabis use [N = 184,765]; cannabis use disorder [2,387 cases / 48,985 controls], type 2 diabetes [74,124 cases / 824 controls]). The MR analysis suggested no effect of lifetime cannabis use (inverse variance weighted odds ratio [95% confidence interval] = 1.00 [0.93-1.09], P-value = 0.935) and cannabis use disorder (OR = 1.03 [0.99-1.08]) on type 2 diabetes. Sensitivity analysis to assess potential pleiotropy led to no substantive change in the estimates. This study adds to the evidence base that cannabis use does not play a causal role in type 2 diabetes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from each study participant. Study protocols for all cohorts were reviewed and approved by the appropriate institutional review boards. Detailed information on patient consent and ethics approval is available in the orginal GWAS (14-17). The summary statistics for the cannabis GWAS (14) are publicly available at https://www.ru.nl/bsi/research/group-pages/substance-use-addiction-food-saf/vm-saf/genetics/international-cannabis-consortium-icc/ (access date: 2020/07/20). The cannabis use disorder data are available at https://ipsych.dk/en/research/downloads/data-download-agreement-ipsych-secondary-phenotypes-cannabis-2019/ (access date: 2020/07/20). The primary type 2 diabetes GWAS (16) summary data are available at http://diagram-consortium.org/downloads.html (access date: 2020/07/20) and the summary data from the second type 2 diabetes GWAS (17) is available at https://cnsgenomics.com/content/data (access date: 2020/07/20). The study adhered to the MR-Strobe statement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe summary statistics for the cannabis GWAS (14) are available at https://www.ru.nl/bsi/research/group-pages/substance-use-addiction-food-saf/vm-saf/genetics/international-cannabis-consortium-icc/ (access date: 2020/07/20). Thr cannabis use disorder data are available at https://ipsych.dk/en/research/downloads/data-download-agreement-ipsych-secondary-phenotypes-cannabis-2019/ (access date: 2020/07/20). The primary type 2 diabetes GWAS (16) summary data are available at http://diagram-consortium.org/downloads.html (access date: 2020/07/20) and the summary data from the second type 2 diabetes GWAS (17) is available from https://cnsgenomics.com/content/data (access date: 2020/07/20).